WHO ICTRP trial
Hemoperfusion effect in treatment of patients with COVID-19
IRCT20110425006280N12 · Iranian Registry of Clinical Trials (IRCT) · Recruiting
Key facts
| Trial ID | IRCT20110425006280N12 |
|---|---|
| Public title | Hemoperfusion effect in treatment of patients with COVID-19 |
| Scientific title | Evaluation of Hemoperfusion effect in treatment of patients with COVID-19 hospitalized in intensive care unit, Randomized clinical trial |
| Primary sponsor | Vice President of Research Guilan university of medical sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Recruiting |
| Study type | interventional |
| Countries | Iran (Islamic Republic of) |
| Conditions | The effect of Hemoperfusion in the treatment of covid-19 disease. COVID-19, virus identified;U07.1 |
| Interventions | Intervention 1: Intervention group includes 10 patients who enter the study after obtaining the informed consent of the patient or her companion and receive the standard COVID-19 treatment regimen along with 3 sessions of hemoperfusion… |
| Registration date | Aug 14, 2021 |
| Target size | 20 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: